

30 May 2024 EMA/CHMP/SAWP/252273/2024 Press Office

Scientific advice and protocol assistance

Adopted during the CHMP meeting 27-30 May 2024

Pre-authorisation: scientific advice and protocol assistance EMA centralised procedures

	1995-2023	2024	Overall total
Scientific Advice	6072	170	6242
Follow-up to Scientific Advice	1928	72	2000
Protocol Assistance	1343	34	1377
Follow-up to Protocol Assistance	719	22	741
EMA/EUnetHTA parallel consultation advice	165	0	165
Qualification of novel methodologies	228	14	242
	10455	313	10767

Outcome of the May 2024 CHMP meeting in relation to scientific advice procedures

Final scientific advice procedures

Substance	Intended indications	Type of request				Topic				
		New		Follow- up						
		SA	PA	SA	PA	Quality	Preclinical	Clinical	Significant benefit	
Advanced Therapy	Treatment of sickle cell disease			x		x				
Advanced Therapy	Treatment of chronic granulomatous disease	x				Х	х	X		
Advanced Therapy	Treatment of pyruvate kinase deficiency		x			X	X	x	x	



Substance	Intended indications	Type of request			Торіс				
		New		Foll up	ow-				
		SA	PA	SA	PA	Quality	Preclinical	Clinical	Significant benefit
Biological	Treatment of adenocarcinoma	x						X	
Biological	Treatment of adenocarcinoma	x						X	
Biological	Treatment of thrombotic thrombocytopenic purpura		X			х			
Biological	Treatment of plasma cell myeloma		x					X	
Biological	Treatment of solid tumor			Х		x		X	
Biological	Treatment of haemophilia A				x	x			
Biological	Prevention of exacerbations chronic obstructive pulmonary disease	x				x	x	x	
Biological	Treatment of emphysema			x				х	
Biological	Prevention of lower respiratory tract disease	x				Х	х	x	
Biological	Prevention of cervical cancer			x				x	
Biological	Prevention of influenza	х						x	
Biological	Treatment of Hidradenitis Suppurativa	x					x		
Biological	Treatment of HNSCC			x				x	
Biological	Treatment of NSCLC	x						x	
Biological	Treatment of psoriasis	x				x		x	
Biological	Treatment of osteogenesis				x			x	
Biological	Treatment of psoriatic	х						x	
Biological	Treatment of colitis			x		x		x	
Biological	Treatment of colitis			x		Х		x	
Chemical	Treatment of NSCLC	Х						x	
Chemical	Treatment of Prader-Willi syndrome		x			Х	х	x	x
Chemical	Prevention of Transthyretin Amyloidosis	Х					х	x	
Chemical	Prevention of heart failure	x					х	x	
Chemical	Treatment of weight management	x					х	x	

Substance	Intended indications	Type of request			Topic				
		New		Foll up	ow-				
		SA	PA	SA	PA	Quality	Preclinical	Clinical	Significant benefit
Chemical	Treatment of idiopathic pulmonary fibrosis (IPF)	х					Х		
Chemical	Prevention of angioedema			x			х	X	
Chemical	Treatment of NSCLC			x			х	X	
Chemical	Treatment of ABCC6 deficiency		x				x	x	
Chemical	Treatment of Head and Neck Cancer	x						x	
Chemical	Diagnosis of AL amyloidosis		x				Х	x	
Chemical	Treatment of overweight			x		x		x	
Chemical	Treatment of hypertension	x					x	x	
Chemical	Treatment of schizophrenia	x					х	x	
Chemical	Treatment of organ transplantation		x				х	x	
Chemical	Treatment of MGMT	x						x	
Chemical	Treatment of Niemann-Pick disease			x				x	
Chemical	Treatment of gangliosidosis			x				x	
Chemical	Treatment of kidney disease	x						х	
Chemical	Treatment of muscular atrophy			x				x	
Chemical	Treatment of muscular atrophy				x			x	
Chemical	Treatment of heart failure	x						x	
Chemical	Treatment of hyperplasia	x					x	x	
Chemical	Treatment of hidradenitis suppurativa			x		x			
Chemical	Treatment of adenocarcinoma	x				x	x	x	
Chemical	Treatment of acute myeloid leukaemia (AML)			X				X	
Chemical	Treatment of infections			x				x	
Chemical	Treatment of polycythaemia vera		×			Х	Х		
Chemical	Treatment of pulmonary arterial hypertension		x				x	х	

Substance	Intended indications	Ту	pe of	requ	est	Topic				
		New		Follow- up						
		SA	PA	SA	PA	Quality	Preclinical	Clinical	Significant benefit	
Chemical	Treatment of NSCLC			x				x		
Chemical	Treatment of Non-alcoholic steatohepatitis	x				Х	Х	х		
Chemical	Treatment of non-small-cell lung cancer	x						х		
Chemical	Treatment of non-small-cell lung cancer	x						X		
Chemical	Treatment of colitis	x				х	Х	х		
Chemical	Treatment of follicular lymphoma		x					х		
Chemical	Treatment of TiO2	x					X			
Chemical	Treatment of insomnia	x				Х		х		
Qualification	Medical tool									
Qualification	Medical tool									

SA: Scientific Advice PA: Protocol Assistance

The above-mentioned 61 Scientific Advice letters – 29 Initial Scientific Advice, 17 Follow-up Scientific Advice, 10 Protocol Assistance letters, 10 Follow-up Protocol Assistance, 2 Qualifications of novel methodologies and 0 EMA/EUnetHTA parallel consultation advice were adopted at the 27-30 May 2024.

New requests for scientific advice procedures

The Committee accepted 66 new Requests for which the procedure started at the SAWP meeting held on 13-16 May 2024. The new requests are divided as follows: 41 Initial Scientific Advice, 12 Follow-up Scientific Advice, 8 Protocol Assistance letters, 5 Follow-up Protocol Assistance, 0 Qualifications of novel methodologies and 0 EMA/EUnetHTA parallel consultation advice.